• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Inflammatory bowel disease events after exposure to interleukin 17 inhibitors secukinumab and ixekizumab: Postmarketing analysis from the RADAR ("Research on Adverse Drug events And Reports") program.

作者信息

Orrell Kelsey A, Murphrey Morgan, Kelm Ryan C, Lee Harrison H, Pease David R, Laumann Anne E, West Dennis P, Nardone Beatrice

机构信息

Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

出版信息

J Am Acad Dermatol. 2018 Oct;79(4):777-778. doi: 10.1016/j.jaad.2018.06.024. Epub 2018 Jun 18.

DOI:10.1016/j.jaad.2018.06.024
PMID:29920313
Abstract
摘要

相似文献

1
Inflammatory bowel disease events after exposure to interleukin 17 inhibitors secukinumab and ixekizumab: Postmarketing analysis from the RADAR ("Research on Adverse Drug events And Reports") program.暴露于白细胞介素17抑制剂司库奇尤单抗和依奇珠单抗后的炎症性肠病事件：来自RADAR（“药物不良事件及报告研究”）项目的上市后分析。
J Am Acad Dermatol. 2018 Oct;79(4):777-778. doi: 10.1016/j.jaad.2018.06.024. Epub 2018 Jun 18.
2
Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies.在使用司库奇尤单抗治疗无效的斑块状银屑病患者中换用依奇珠单抗的疗效与安全性：一项关于白细胞介素17A拮抗剂疗法的多中心回顾性研究
J Am Acad Dermatol. 2018 Jul;79(1):155-157. doi: 10.1016/j.jaad.2018.01.003. Epub 2018 Jan 4.
3
Paradoxical Reactions: Anti-Tumor Necrosis Factor Alpha Agents, Ustekinumab, Secukinumab, Ixekizumab, and Others.矛盾反应：抗肿瘤坏死因子α药物、乌司奴单抗、司库奇尤单抗、依奇珠单抗及其他药物。
Curr Probl Dermatol. 2018;53:49-63. doi: 10.1159/000479475. Epub 2017 Nov 7.
4
Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease.白细胞介素-17抑制：在银屑病和炎症性肠病中的作用。
J Dermatolog Treat. 2018 Feb;29(1):13-18. doi: 10.1080/09546634.2017.1329511. Epub 2017 May 31.
5
Emergence of Inflammatory Bowel Disease During Treatment With Secukinumab.在使用司库奇尤单抗治疗期间出现炎症性肠病。
J Crohns Colitis. 2018 Aug 29;12(9):1131-1133. doi: 10.1093/ecco-jcc/jjy063.
6
T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.向 FDA AERS 报告的使用肿瘤坏死因子-α（TNF-α）抑制剂的 T 细胞非霍奇金淋巴瘤：REFURBISH 研究结果。
Am J Gastroenterol. 2013 Jan;108(1):99-105. doi: 10.1038/ajg.2012.334. Epub 2012 Oct 2.
7
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.依奇珠单抗治疗中重度斑块状银屑病的 3 期临床试验。
N Engl J Med. 2016 Jul 28;375(4):345-56. doi: 10.1056/NEJMoa1512711. Epub 2016 Jun 8.
8
Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review.白细胞介素-17（IL-17）抑制剂治疗斑块状银屑病的综述
Skin Therapy Lett. 2015 Jan-Feb;20(1):1-5.
9
Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.抗白细胞介素-17 单克隆抗体依奇珠单抗治疗慢性斑块状银屑病。
N Engl J Med. 2012 Mar 29;366(13):1190-9. doi: 10.1056/NEJMoa1109997.
10
The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.白细胞介素-17在银屑病发病机制中的作用及斑块状银屑病白细胞介素-17抑制剂治疗进展
J Cutan Med Surg. 2016 Nov;20(6):509-516. doi: 10.1177/1203475416651605. Epub 2016 May 20.

引用本文的文献

1
Assessing brodalumab in the treatment of primary sclerosing cholangitis (SABR-PSC pilot study): protocol for a single-arm, multicentre, pilot study.评估布罗达单抗治疗原发性硬化性胆管炎（SABR-PSC 试点研究）：一项单臂、多中心试点研究的方案
BMJ Open Gastroenterol. 2025 Mar 3;12(1):e001596. doi: 10.1136/bmjgast-2024-001596.
2
New-Onset, Treatment-Resistant Inflammatory Bowel Disease after Administration of Secukinumab for Plaque Psoriasis: A Case Report and Review of the Existing Literature.司库奇尤单抗治疗斑块状银屑病后新发的、难治性炎症性肠病：一例报告及现有文献综述
Mediterr J Rheumatol. 2024 Mar 31;35(1):150-155. doi: 10.31138/mjr.030124.ntt. eCollection 2024 Mar.
3
Molecularly Targeted Therapies for Inflammatory Cutaneous Granulomatous Disorders: A Review of the Evidence and Implications for Understanding Disease Pathogenesis.
炎症性皮肤肉芽肿性疾病的分子靶向治疗：证据综述及对理解疾病发病机制的启示
JID Innov. 2023 Aug 10;3(5):100220. doi: 10.1016/j.xjidi.2023.100220. eCollection 2023 Sep.
4
Colonic Dilatation Complicating Acute Severe Ulcerative Colitis Managed Successfully with Accelerated Infliximab Dosing.结肠扩张并发急性重症溃疡性结肠炎，通过加速英夫利昔单抗给药成功治疗
Case Rep Gastroenterol. 2023 Feb 7;17(1):82-88. doi: 10.1159/000529152. eCollection 2023 Jan-Dec.
5
A Review of the Safety of Interleukin-17A Inhibitor Secukinumab.白细胞介素-17A抑制剂司库奇尤单抗的安全性综述
Pharmaceuticals (Basel). 2022 Nov 7;15(11):1365. doi: 10.3390/ph15111365.
6
Should we be concerned about gastrointestinal-related adverse events in patients with plaque psoriasis receiving secukinumab therapy? A retrospective, real-life study.我们是否应该关注接受司库奇尤单抗治疗的斑块型银屑病患者的胃肠道相关不良事件？一项回顾性、真实世界研究。
Dermatol Ther. 2022 Nov;35(11):e15794. doi: 10.1111/dth.15794. Epub 2022 Sep 10.
7
The Treatment with Interleukin 17 Inhibitors and Immune-Mediated Inflammatory Diseases.白细胞介素17抑制剂与免疫介导的炎症性疾病的治疗
Curr Issues Mol Biol. 2022 Apr 26;44(5):1851-1866. doi: 10.3390/cimb44050127.
8
Systematic Review and Meta-Analysis of Inflammatory Bowel Disease Adverse Events with Anti-Interleukin 17A Agents and Tumor Necrosis Factor Inhibitors in Rheumatic Disease and Skin Psoriasis.炎症性肠病不良事件与抗白细胞介素17A药物以及肿瘤坏死因子抑制剂在风湿性疾病和皮肤银屑病中的系统评价与荟萃分析
Rheumatol Ther. 2021 Dec;8(4):1603-1616. doi: 10.1007/s40744-021-00360-6. Epub 2021 Aug 26.
9
Emerging Molecular Targets for the Treatment of Refractory Sarcoidosis.治疗难治性结节病的新兴分子靶点
Front Med (Lausanne). 2020 Nov 24;7:594133. doi: 10.3389/fmed.2020.594133. eCollection 2020.
10
Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors.接受白细胞介素-17抑制剂治疗的银屑病患者的炎症性肠病
Drugs Context. 2020 Apr 21;9. doi: 10.7573/dic.2020-2-1. eCollection 2020.